IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Medical announced positive clinical data for its ProSense® cryoablation system at ECIO 2026, showing 89.4% recurrence-free rate for kidney tumors ≤3 cm and 100% excellent cosmetic outcomes in breast cancer patients. The company also reported 92.9% fibroadenoma volume reduction at 12 months. A dedicated breast cryoablation course was held for the first time at the conference, highlighting growing clinical validation and commercial interest in the technology.

05/19/2026, 8:30 AM • Benzinga

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Medical Ltd. (NASDAQ: ICCM) has been granted an additional 180-day compliance period until November 9, 2026 to regain compliance with Nasdaq's minimum $1.00 bid price requirement. The company failed to meet the requirement during the first 180-day period ending May 11, 2026, and may implement a reverse share split to cure the deficiency.

05/13/2026, 4:30 PM • Benzinga

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical reported Q1 2026 results with global revenue growth of 26% to $911,000 and North America sales up 84%. Following FDA clearance for breast cancer treatment, active U.S. customer accounts increased 46% to 19 accounts. The company is expanding its U.S. sales footprint to eight regions and expects its ChoICE post-marketing study to accelerate adoption. However, net loss widened to $4.3 million and cash decreased to $8.1 million.

05/12/2026, 8:30 AM • Benzinga

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Medical showcased its ProSense® cryoablation system at the American Society of Breast Surgeons 2026 Annual Meeting in Seattle. The company reported U.S. revenue for ProSense® systems and cryoprobes increased more than 30% in Q1 2026 compared to Q1 2025. ProSense® is the only FDA-cleared minimally invasive treatment for low-risk breast cancer and has been included in the ASBrS Resource Guide as a recommended treatment option.

05/05/2026, 8:30 AM • Benzinga

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

IceCure Medical announced positive results from its ICESECRET clinical trial of ProSense® cryoablation system for treating small renal masses in kidney cancer patients. The study of 112 patients showed an 83.9% recurrence-free rate at median 4-year follow-up, with 89.4% recurrence-free rate in the subgroup of patients with tumors ≤3 cm and no prior kidney cancer. Full results will be presented at the European Conference on Interventional Oncology in April 2026.

03/25/2026, 8:30 AM • Benzinga

IceCure Appoints Meir Peleg as Chief Financial Officer

IceCure Medical (NASDAQ: ICCM) announced the appointment of Meir Peleg as Chief Financial Officer effective May 17, 2026. Peleg brings over 20 years of financial leadership experience with public companies and capital markets expertise. The company also plans to appoint Dr. Richard Fine as Medical Director to lead breast indications. These appointments come as IceCure experiences strong commercial momentum for its ProSense® cryoablation system following FDA clearance for low-risk breast cancer treatment.

03/24/2026, 8:30 AM • Benzinga

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

IceCure Medical Ltd. (NASDAQ: ICCM), a developer of minimally-invasive cryoablation technology for tumor destruction, announced it will release its 2025 full-year financial and operating results on March 17, 2026, before market open, followed by a conference call at 11:00 a.m. EDT.

03/10/2026, 8:30 AM • Benzinga

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

The American Society of Breast Surgeons updated its 2026 Resource Guide to recommend cryoablation as a treatment option for selected patients with biologically low-risk early-stage breast cancer. IceCure Medical's ProSense® cryoablation system, which received FDA clearance in October 2025 for treating low-risk breast cancer in patients aged 70 and above, is positioned to benefit from this clinical endorsement and expected acceleration in commercial adoption.

03/09/2026, 8:30 AM • Benzinga

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

IceCure Medical announced publication of an independent study in PLOS One showing its ProSense® cryoablation system achieved 92.9% volume reduction of breast fibroadenomas one year post-treatment. The study, conducted in Hungary, evaluated larger lesions using multiple cryoprobe relocations and may impact treatment guidelines for non-cancerous breast tumors. IceCure estimates cryoablation could address approximately 63,000 fibroadenoma cases annually in the U.S.

03/02/2026, 8:30 AM • Benzinga

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

IceCure Medical (NASDAQ: ICCM) announced that CFO Ronen Tsimerman will depart after nine years of service to pursue new opportunities. Tsimerman will remain in his role until a successor is appointed. The company has identified candidates for the position and some have advanced to board interviews. During his tenure, Tsimerman helped achieve key milestones including the company's Nasdaq listing, fundraising for the ICE3 study, and FDA marketing clearance of ProSense® for low-risk breast cancer treatment in late 2025.

02/09/2026, 4:30 PM • Benzinga

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

IceCure Medical announced that the American Society of Breast Surgeons (ASBrS) has proposed updated treatment guidelines that include cryoablation for low-risk breast cancer in patients aged 70 and above. The proposed guidelines, pending finalization after a January 23, 2026 comment period, align with the FDA's October 2025 marketing authorization for IceCure's ProSense® cryoablation system. The company expects the guidelines to accelerate physician adoption, patient access, and reimbursement coverage for its minimally invasive breast cancer treatment technology.

01/28/2026, 8:30 AM • Benzinga

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

IceCure Medical expects record fourth quarter sales in North America following FDA clearance of ProSense® Cryoablation for low-risk breast cancer treatment, with strong interest from medical institutions and growing market demand.

12/17/2025, 8:30 AM • Benzinga

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

IceCure Medical presented four independent studies at the Radiological Society of North America's Annual Meeting, highlighting the effectiveness of their ProSense® Cryoablation technology for non-surgical breast cancer treatment in patients who are not eligible for surgery.

12/10/2025, 8:30 AM • Benzinga

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

IceCure Medical received a patent allowance in China for a novel cryogen flow control technology that optimizes patient cryoablation outcomes, enhancing temperature control and treatment effectiveness for tumor destruction.

12/05/2025, 8:30 AM • Benzinga

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

IceCure Medical received regulatory approval in Switzerland for its ProSense® Cryoablation System, expanding its market access for cancer treatment across breast, lung, liver, and kidney cancer indications.

11/18/2025, 8:30 AM • Benzinga